Cipher receives Patent Notice of Allowance for CIP-ISOTRETINOIN
"Having the U.S. patent allowed represents an important milestone on our path to commercialization for CIP-ISOTRETINOIN," said Larry Andrews, President & CEO of Cipher. "It also reinforces that the product is truly differentiated from currently marketed formulations."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.